<DOC>
	<DOC>NCT00645723</DOC>
	<brief_summary>Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.</brief_summary>
	<brief_title>Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii</brief_title>
	<detailed_description>Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<criteria>Diagnose of VAP due A. baumannii or A. baumannii and another microorganism carbapenems resistant. Clinical Pulmonary Infection Score (CPIS) &gt; 6 Allergy to colistin. Asthma Shock status Diagnose of VAP due A. baumannii colistin resistant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Acinetobacter baumanii</keyword>
	<keyword>Ventilator-associated pneumonia</keyword>
</DOC>